Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination

Tomohiro Bando; Reoto Takei; Yoshikazu Mutoh; Hajime Sasano; Yasuhiko Yamano; Toshiki Yokoyama; Toshiaki Matsuda; Kensuke Kataoka; Tomoki Kimura; Yasuhiro Kondoh

doi:10.1183/13993003.02806-2021

Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination

Eur Respir J. 2022 Mar 10;59(3):2102806. doi: 10.1183/13993003.02806-2021. Print 2022 Mar.

Affiliations

¹ Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.
² Dept of Infectious Diseases, Tosei General Hospital, Seto, Japan.
³ Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan kondoh@tosei.or.jp.

Abstract

Although the association between acute exacerbation of interstitial lung disease and vaccination is not yet clarified, this is the first case report describing the possibility that SARS-CoV-2 vaccination may trigger acute exacerbation https://bit.ly/3tpu6Cz

Publication types

Letter
Comment

MeSH terms

COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Humans
Idiopathic Pulmonary Fibrosis*
SARS-CoV-2
Vaccination / adverse effects

Substances

COVID-19 Vaccines